- mail us help@24marketresearch.com
- Int'l 1(332) 2424 294 (Int'l)
TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
MARKET INSIGHTS
Global solid-phase oligonucleotide synthesis market was valued at USD 439 million in 2024 and is projected to reach USD 1,378 million by 2032, growing at a CAGR of 18.2% during the forecast period. While North America currently dominates the market with the U.S. as a key revenue generator, China is emerging as the fastest-growing region due to increasing biotechnology investments.
Solid-phase oligonucleotide synthesis is a foundational technology for creating custom DNA and RNA strands, where nucleotides are sequentially added to a growing chain attached to an insoluble support. This method enables precise manufacturing of primers, probes, linkers, and therapeutic oligonucleotides with applications ranging from PCR diagnostics to antisense therapies. The market comprises five key product segments: primers (holding the largest share), probes, intermediate-scale synthesis oligos, large-scale synthesis oligos, and linkers/adaptors.
Market expansion is primarily driven by the booming synthetic biology sector, which saw 35% year-over-year growth in 2023, along with increasing adoption in pharmaceutical R&D for oligonucleotide-based drugs. However, high synthesis costs and technical limitations in long-chain oligonucleotide production remain key challenges. Recent technological advancements, including automated synthesizers from market leaders like Thermo Fisher Scientific (GeneArt) and Eurofins Genomics, are addressing these constraints while expanding commercial applications.
Rising Demand for Therapeutic Oligonucleotides to Accelerate Market Expansion
The global solid-phase oligonucleotide synthesis market is experiencing significant growth due to the increasing demand for therapeutic oligonucleotides in precision medicine. With over 300 oligonucleotide-based therapeutics currently in clinical development, pharmaceutical companies are heavily investing in this technology. The therapeutic potential spans rare genetic disorders, oncology, and antiviral applications, with antisense oligonucleotides accounting for nearly 40% of ongoing clinical trials. Recent FDA approvals like Casimersen for Duchenne muscular dystrophy and Inclisiran for hypercholesterolemia demonstrate the growing clinical validation of these therapies.
Technological Advancements in Synthesis Platforms Fueling Market Growth
Innovations in solid-phase synthesis technology are dramatically improving yield, purity, and cost-efficiency. Modern automated synthesizers can now produce sequences up to 200 nucleotides with coupling efficiencies exceeding 99.5%. Leading manufacturers have introduced high-throughput platforms capable of synthesizing over 1,000 oligonucleotides simultaneously, reducing production costs by approximately 30-40%. These advancements are particularly crucial as the demand for synthetic DNA and RNA tools in research and diagnostics continues to grow at an annual rate of 15-20%.
COVID-19 Pandemic Accelerates Demand for Diagnostic Oligonucleotides
The pandemic created an unprecedented need for synthetic oligonucleotides used in PCR testing and vaccine development. During peak demand, manufacturers reported 300-400% increases in orders for probe and primer synthesis. This surge highlighted the critical role of solid-phase synthesis in global health preparedness, with governments and private sectors subsequently increasing investments in domestic oligonucleotide production capacity. The diagnostic oligonucleotide market segment is expected to maintain a 12% CAGR through 2027 as pandemic preparedness becomes a permanent focus area.
High Capital Requirements and Operational Costs Limit Market Accessibility
Establishing an oligonucleotide synthesis facility requires substantial capital investment, with automated synthesizers ranging from $200,000 to $1 million per unit depending on throughput capacity. Additionally, the cost of high-purity phosphoramidites and specialized reagents contributes to an average production cost of $0.15-$0.30 per base for research-grade oligos. These financial barriers prevent many smaller research institutions and biotech startups from establishing in-house synthesis capabilities, creating dependence on contract manufacturing organizations.
Complex Quality Control Requirements Pose Manufacturing Challenges
Therapeutic-grade oligonucleotide production requires rigorous quality control procedures that add significant time and cost to manufacturing. Each batch must undergo multiple analytical tests including mass spectrometry, HPLC purification, and endotoxin testing. These processes can extend production timelines by 2-3 weeks and add 30-50% to the total manufacturing cost. Regulatory requirements continue to evolve, creating additional compliance challenges for manufacturers operating in multiple geographic markets.
Intellectual Property Disputes Create Market Uncertainty
The oligonucleotide synthesis landscape is characterized by intense patent litigation, particularly concerning chemical modifications and delivery technologies. Over 150 active patents cover various aspects of synthesis chemistry and modifications, creating a complex IP landscape. This has led to several high-profile legal disputes between major manufacturers, which can delay product development and create market instability. Emerging markets face particular challenges in navigating these IP restrictions while trying to develop local manufacturing capabilities.
Emerging Economies Present Untapped Growth Potential
Developing regions currently represent less than 20% of the global oligonucleotide synthesis market but are projected to grow at nearly double the global average rate. Government initiatives in countries like India and China to build domestic biotech capabilities are creating new opportunities. The Asia-Pacific region is expected to account for 35% of market growth through 2030, supported by increasing R&D investments and the establishment of new contract manufacturing facilities serving both local and global markets.
Convergence With CRISPR and Gene Editing Technologies Opens New Applications
The integration of synthetic oligonucleotides with emerging gene editing platforms presents significant growth opportunities. Synthetic guide RNAs for CRISPR systems currently represent the fastest-growing product segment, with demand increasing by over 50% annually. This convergence is driving innovation in modified nucleotide chemistry to improve editing efficiency and specificity. Several companies are developing integrated platforms that combine oligonucleotide synthesis with gene editing reagents, creating streamlined workflows for research and therapeutic applications.
Customized Modification Services Create Value-Added Market Segments
There is growing demand for specialty oligonucleotides incorporating novel modifications to enhance stability, reduce immunogenicity, or improve targeting. Modified oligonucleotides now account for nearly 60% of therapeutic development programs and command premium pricing. Manufacturers offering comprehensive modification portfolios including phosphorothioates, 2'-O-methyl, and locked nucleic acids are capturing higher-margin business segments. This trend is driving increased R&D investment in novel nucleotide chemistries and conjugation technologies.
MARKET CHALLENGES
Supply Chain Vulnerabilities Threaten Market Stability
The oligonucleotide synthesis industry faces significant supply chain risks, particularly for phosphoramidites and other specialty reagents. Over 70% of key raw materials are sourced from a limited number of suppliers, creating potential bottlenecks. Recent disruptions have led to lead time extensions from 2-3 weeks to 3-6 months for some critical components. This fragility was exposed during the pandemic when shortages caused delays in diagnostic test production, prompting calls for greater supply chain diversification and strategic stockpiling.
Other Challenges
Regulatory Complexity for Therapeutic Applications
The regulatory pathway for therapeutic oligonucleotides remains complex and inconsistently applied across regions. Requirements for chemistry, manufacturing, and controls (CMC) documentation vary significantly between regulatory agencies, forcing manufacturers to maintain multiple version of technical files. Unexpected requests for additional stability or toxicity data can delay approvals by 12-18 months and add millions in development costs.
Technical Limitations in Large-Scale Production
While solid-phase synthesis is ideal for research-scale production, scaling to commercial therapeutic quantities presents technical hurdles. Batch-to-batch consistency becomes increasingly challenging at larger scales, with yield variability of 15-20% common in industrial production. These challenges have led to failed batches costing upwards of $1 million, driving interest in alternative synthesis methods as production volumes increase.
Primers Segment Dominates the Market Due to Widespread Use in PCR and Gene Synthesis
The market is segmented based on type into:
Primers
Probes
Intermediate-scale Synthesis Oligos
Large-scale Synthesis Oligos
Linkers and Adaptors
Commercial Segment Leads Due to Increasing Demand from Biotech and Pharmaceutical Companies
The market is segmented based on application into:
Commercial
Academic Research
Biotechnology and Pharmaceutical Companies Account for Major Market Share
The market is segmented based on end user into:
Biotechnology Companies
Pharmaceutical Companies
Academic and Research Institutions
Diagnostic Laboratories
Contract Research Organizations
Phosphoramidite Method Remains Industry Standard
The market is segmented based on synthesis method into:
Phosphoramidite Method
H-Phosphonate Method
Solid-phase Synthesis with Liquid-phase Deprotection
Continuous Flow Method
Strategic Expansion and Technological Innovation Drive Market Competition
The global solid-phase oligonucleotide synthesis market features a dynamic competitive landscape, characterized by the presence of established biotech firms and emerging players competing for market share. In 2024, the market was valued at $439 million and is projected to grow at an impressive CAGR of 18.2%, reaching $1.38 billion by 2032. This growth trajectory is fueled by increasing demand for synthetic DNA/RNA in therapeutics, diagnostics, and research applications.
GenScript currently leads the market, leveraging its comprehensive service portfolio and global manufacturing capabilities. The company's dominance stems from its high-throughput synthesis platforms and custom oligonucleotide design expertise, serving both pharmaceutical and academic clients worldwide. Meanwhile, GeneArt (Thermo Fisher Scientific) maintains a strong position through its proprietary synthesis technologies and integration with parent company resources.
The competitive environment is intensifying as mid-tier players like Eurofins Genomics and BBI Solutions expand their technological capabilities. Eurofins has particularly strengthened its market position through strategic acquisitions and investments in automated synthesis platforms. These companies are actively competing on factors including turnaround time, purity specifications, and price competitiveness to capture greater market share.
Emerging market dynamics include increased vertical integration, with several key players now offering end-to-end solutions from sequence design to modified oligo production. ATUM (DNA2.0) has differentiated itself through its bioinformatics-driven design platform, while SBS Genetech has gained traction in the Asian market through competitive pricing and localized service networks.
GenScript (U.S.)
GeneArt (Thermo Fisher Scientific) (U.S.)
Renesas Electronics Corporation (Japan)
DNA 2.0 (ATUM) (U.S.)
OriGene Technologies (U.S.)
BBI Solutions (U.K.)
Genewiz (U.S.)
Eurofins Genomics (Luxembourg)
Gene Oracle (U.S.)
SBS Genetech (China)
The solid-phase oligonucleotide synthesis market is experiencing significant growth due to the rising demand for custom oligonucleotides across therapeutic and diagnostic applications. Synthetic oligonucleotides are crucial for gene synthesis, PCR, DNA sequencing, and antisense therapies, with the therapeutics segment accounting for approximately 42% of total demand in 2024. The market is further propelled by advancements in automated synthesis platforms, enabling high-throughput production with reduced error rates below 0.5%. Pharmaceutical companies are increasingly adopting solid-phase synthesis for developing RNA-based therapeutics, including mRNA vaccines and siRNA drugs, contributing to the projected CAGR of 18.2% through 2032.
Therapeutic Applications in Precision Medicine
There is growing adoption of synthetic oligonucleotides in precision medicine, particularly for rare genetic disorders and oncology treatments. Antisense oligonucleotide (ASO) therapies have shown clinical success in treating diseases like spinal muscular atrophy and Duchenne muscular dystrophy, with over 15 ASO drugs receiving FDA approval since 2020. Furthermore, the development of modified nucleotides with enhanced stability and target specificity is expanding therapeutic possibilities. The increasing prevalence of genetic disorders, affecting nearly 400 million people worldwide, is driving investments in oligonucleotide-based therapies, creating sustained demand for synthesis technologies.
The market is witnessing rapid technological evolution, with key players introducing next-generation synthesizers capable of producing oligonucleotides up to 200 bases with 99.9% coupling efficiency. Recent innovations include microfluidics-based systems that reduce reagent consumption by 60% while improving synthesis speed. Additionally, the integration of machine learning algorithms for sequence optimization and error correction is enhancing yield and purity. These advancements are particularly crucial as the industry shifts toward GMP-compliant manufacturing to meet regulatory requirements for clinical-grade oligonucleotides. The convergence of synthetic biology and nucleotide chemistry is creating new opportunities in mRNA vaccine production and CRISPR guide RNA synthesis, further driving market growth.
North America
The North American solid-phase oligonucleotide synthesis market is the most advanced, driven by strong biotech R&D investments, pharmaceutical innovation, and FDA-approved therapeutic applications. The U.S. accounts for the majority share of regional demand, with an estimated market valuation exceeding $150 million in 2024. Leading players like GeneArt (Thermo Fisher) and GenScript dominate the landscape, providing high-purity oligonucleotides for diagnostics, gene editing, and drug development. While academic research institutes contribute significantly to demand, commercial applications—particularly in mRNA vaccines and antisense therapies—are accelerating market expansion. Challenges include supply chain complexities and the need for scalable synthesis platforms to meet growing clinical trial requirements. However, the region’s regulatory clarity and intellectual property protections continue to attract investment.
Europe
Europe maintains a robust market, characterized by stringent quality standards and collaborations between academic institutions and biotech firms. The region benefits from centralized regulatory oversight (EMA) and initiatives like Horizon Europe, which funds oligonucleotide-based therapeutic research. Germany, the U.K., and France are key markets, with Eurofins Genomics and DNA 2.0 (ATUM) playing pivotal roles. Demand is fueled by increasing applications in personalized medicine and CRISPR-based technologies, though Brexit-related trade disruptions have introduced minor supply chain challenges. Sustainability is gaining traction, with manufacturers gradually shifting toward greener synthesis methods to align with the EU’s Green Deal objectives. Nonetheless, pricing pressures from Asia-based competitors remain a concern for local suppliers.
Asia-Pacific
As the fastest-growing region, Asia-Pacific is projected to achieve a CAGR exceeding 20%, propelled by China’s biopharmaceutical boom and India’s expanding contract research organizations (CROs). China dominates production and consumption, leveraging lower manufacturing costs and government-backed genomics initiatives like the China National GeneBank. While Japan and South Korea focus on precision medicine applications, Southeast Asia emerges as a hub for cost-efficient oligonucleotide synthesis services. Challenges include uneven quality control and intellectual property risks, but the region’s sheer scale and rising R&D investments position it as a critical market. Local players like SBS Genetech compete with global giants by offering competitively priced primers and probes.
South America
The South American market remains nascent but shows promise due to increasing biotechnology adoption in Brazil and Argentina. Academic research drives most demand, though commercial applications—such as agricultural biotechnology and veterinary diagnostics—are emerging. Infrastructure limitations and reliance on imported synthesis equipment hinder growth, but localized production efforts led by firms like Bio Basic aim to reduce dependencies. Economic instability and currency fluctuations further complicate long-term planning for market entrants, yet the region’s unmet medical needs present opportunities for oligonucleotide-based therapeutics in infectious disease management.
Middle East & Africa
This region represents a developing market, with growth centered in Israel, Saudi Arabia, and the UAE, where genomics research and precision medicine initiatives are gaining momentum. Israel’s thriving biotech sector—supported by firms like ChemGenes—leads in innovative synthesis techniques. In contrast, Africa’s market is constrained by limited infrastructure and funding, though partnerships with global health organizations aim to expand oligonucleotide use in infectious disease testing. Regulatory frameworks are still evolving, but increasing healthcare investments suggest gradual market maturation, particularly for diagnostic probes and research-grade oligos.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Genescript, GeneArt (Thermofischer), Renesas Electronics Corporation, DNA 2.0 (ATUM), OriGene, BBI, Genewiz, Eurofins Genomics, Gene Oracle, SBS Genetech, and Bio Basic.
-> Key growth drivers include rising demand for synthetic DNA/RNA in therapeutics, diagnostics, and research applications, along with technological advancements in synthesis techniques.
-> North America holds the largest market share, while Asia-Pacific is expected to witness the highest growth rate during the forecast period.
-> Emerging trends include automated synthesis platforms, high-throughput technologies, and increasing adoption in personalized medicine applications.
Frequently Asked Questions ?
